Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.54 |
| ▸ | AXL | P30530 | 3/20 | 0.54 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.54 |
| ▸ | MERTK | Q12866 | 2/20 | 0.54 |
| ▸ | MST1R | Q04912 | 13/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285562 | 0.91 | MST1R (0.54) | METAXLTYRO3MERTKMST1R | |
| SCHEMBL4734586 | 0.89 | MST1R (0.52) | METAXLTYRO3MERTKMST1R | |
| SCHEMBL2280609 | 0.87 | MST1R (0.49) | METAXLTYRO3MERTKMST1R | |
| SCHEMBL2282947 | 0.84 | MET (0.63) | METAXLTYRO3MERTK | |
| SCHEMBL14206055 | 0.80 | MET (0.59) | METAXLMERTKKITKDR | |
| SCHEMBL12376921 | 0.80 | MST1R (0.58) | METAXLTYRO3MERTKMST1R | |
| SCHEMBL2282337 | 0.79 | MET (0.56) | METAXLTYRO3MERTKMST1R | |
| SCHEMBL3111213 | 0.79 | AXL (0.66) | METAXLTYRO3MERTK | |
| SCHEMBL2282030 | 0.78 | MET (0.54) | METAXLMST1RKITKDR | |
| SCHEMBL2281518 | 0.77 | MST1R (0.56) | METMST1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885AXL 102/4885TYRO3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.